for 6 months in 45 patients with CIDP. 41 The primary outcome, discontinuation due to any cause, was higher with methylprednisolone than IVIg (52% vs 13%; relative risk, 0.54; 95% CI, 0.34-0.87).

The diagnosis of CIDP is suspected with a history of progressive sensorimotor neuropathy. Physical examination consistent with distal sensory loss in the upper and lower extremities, in conjunction ...

CIDP is often considered the chronic form of Guillain-Barré Syndrome and, as such, can be more problematic in that it lasts longer, causes more damage and is more difficult to recover from.

Dublin, March 05, 2025 (GLOBE NEWSWIRE) -- The "Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline Insight, 2025" report has been added to ResearchAndMarkets.com's offering.

CIDP is a rare autoimmune neurological disorder that causes progressive muscle weakness and sensory loss due to damage to the peripheral nerves. The initial data readout, encompassing pooled data ...

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a progressive or relapsing neuropathy likely caused by an autoimmune attack on the peripheral nerves. A number of treatment ...

In total, 1435 patients with CIDP and 4305 controls were included. Data revealed that the all-cause health care resource utilization (HCRU) for those with CIDP was more than 3 times the HCRU for ...

Vyvgart Hytrulo (efgartigimod alfa/hyaluronidase) is the first drug in the FcRn blocker class to treat CIDP, a rare autoimmune disease of the peripheral nervous system that causes fatigue ...

Today’s results show that deeper IgG reduction leads to deeper responses in MG and CIDP. Beyond the results in MG and CIDP, we believe that our core thesis - that deeper IgG reduction ...